Unregulated Mounjaro vials sold via Telegram from Andorra to Spain

An investigation by El País, relayed in local Andorran media, says Mounjaro — a tirzepatide product prescribed for type 2 diabetes that is also used off‑label for weight loss — is being sold from Andorra to customers in Spain through Telegram groups without prescriptions or medical supervision. The seller, identified only by the name “Lorenzo,” told the paper he has distributed the drug from his Andorra residence for about two years and initially began “to help my sister,” later promoting it as a “solution for athletes.”

According to the report, Lorenzo charges €175 for a vial he described as two milligrams of Mounjaro, plus €14 for shipping, and accepts payment via apps such as Revolut. He also claimed to sell tax‑free and at prices below the legal market. Diari d’Andorra notes that the Telegram channel advertised a 2.5 mg presentation for the same €175 price, while the official retail price in Andorra for a 2.5 mg vial is reported at roughly €270 and about €450 for a 15 mg presentation; Mounjaro is not covered by Andorra’s social insurance scheme (CASS).

El País and local reporting say the product being offered is not the prefilled pen approved by health authorities but a lyophilized (powder) vial format that must be reconstituted. That powdered form is not authorised in Spain, and specialists warn its composition and production conditions are unknown. Endocrinologist Cristóbal Morales and other clinicians cited in the coverage emphasise that these formats may not meet safety standards and that improper handling, storage or reconstitution can affect potency and sterility.

Health authorities and physicians warn of risks from use without medical oversight: incorrect dosing, adverse reactions, interactions with other conditions or medications, and exposure to falsified or contaminated products. The Spanish Agency of Medicines has publicly cautioned against acquiring and using such drugs outside authorised channels.

Andorra’s Ministry of Health told Diari d’Andorra that routine inspections of pharmacies have not detected irregularities in legitimate dispensing, either in‑store or online, and reiterated that a prescription is required. The ministry stressed the importance of medical supervision and warned that unsupervised use poses health risks. Administrators of some Telegram groups have said they sell a “laboratory” format not linked to licensed channels and defended lower pricing as a humanitarian measure rather than profit‑driven.

The coverage places Spain, Andorra and Gibraltar among hotspots for a parallel market that has expanded alongside social media interest in GLP‑1 and GIP receptor agonists such as Mounjaro and Ozempic for weight loss. Public‑health observers point to unequal access and high demand as drivers of this black market. The World Health Organization has issued guidance underscoring that these drugs can be effective under medical supervision and called for equitable access to reduce unsafe informal channels.

Physicians and regulators urge patients to obtain tirzepatide and similar medicines only through authorised prescriptions and licensed pharmacies, with appropriate medical follow‑up to manage dosing, monitor side effects and ensure product quality.